profit from every €100 of sales.
€0€100
MedinCell
€29.76-0.80% today
+18.2% since Dec 19, 25
1-year low €20.241-year high €30.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What MedinCell sold, what it kept, and what it did with the cash.
Sales went from €4.09 million in 2022 to €25.5 million in 2025, with -€18.4 million of profit last year.
SalesProfit
MedinCell vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| MedinCell | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MedinCell's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 10 | 9 | 26 | |
| 4 | 10 | 9 | 26 | |
| -24 | -24 | -21 | -11 | |
| -21 | -26 | -19 | -11 | |
| -25 | -32 | -25 | -18 | |
| -1.00 | -1.27 | -0.86 | -0.62 | |
| 100.0% | 100.0% | 100.0% | 100.0% | |
| -582.3% | -241.8% | -229.0% | -42.4% | |
| -606.5% | -321.9% | -273.3% | -72.2% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 44 | 29 | 37 | 90 |
| Cash | 25 | 6 | 19 | 59 |
| Total debt | 47 | 55 | 59 | 59 |
| Total liabilities | 58 | 72 | 78 | 107 |
| -13 | -42 | -41 | -16 | |
| 25 | 25 | 29 | 30 | |
| -50.5% | -170.4% | -84.1% | -23.3% | |
| 185.5% | 75.7% | 61.3% | 112.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -21 | -12 | 19 | |
| 2 | 1 | 1 | 2 | |
| -23 | -22 | -13 | 18 | |
| Dividends paid | – | – | – | – |
| 0 | – | 0 | – | |
| 2 | 2 | 3 | 3 |
Valuation
- –
- –
- –
- -60.8×
- 41.9×
- 60.1×
- –
- 1.7%
- -1.7%
- –
Profitability
- 100.0%
- -42.4%
- -72.2%
- –
- -23.3%
- -82.1%
- –
- –
- –
- –
Growth
- +84.1%
- –
- –
- –
- +6.0%
Financial health
- -0.0×
- -3.59
- –
- -2.6×
- 2.70
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 953
Bottom 8%of 877
Top 7%of 871
Top 45%of 988
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
40No pass
Philip Fisher
46No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
32No pass
Terry Smith
33No pass
Questions about MedinCell
Is MedinCell a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MedinCell AI analysis
What does MedinCell do?
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It is in Biotechnology, based in Jacou, France, with 145 employees.
Is MedinCell stock halal?
Yes. MedinCell passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
Who are MedinCell's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MedinCell's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.